RLMDRelmada Therapeutics, Inc.
$3.16+59% 1Y
$3.16
$1.9352 weeks$7.86
RLMD in its own filings
RLMD's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
255
Events found in the filings · across 606 filings · the record starts in 2012
- Hard flags
- 3
Hard flags
- Most recent filing
- Sep 8, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 10, 2012
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Change in certifying accountant3 occurrences
- 2025-05-12
- Late periodic report2 occurrences
- 2014-04-14
- Delisting notice / listing-rule failure2 occurrences
- 2025-07-23
- SEC comment-letter activity29 occurrences
- 2026-04-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Dated: September 8, 2026 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer.Other event · Form 8-K
- Aug 6, 2026Relmada Therapeutics Reports Second Quarter.Earnings release · press release
- Jul 28, 2026Relmada Therapeutics Appoints Uro-Oncology Leader.Regulation FD disclosure · press release
- May 28, 2026On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “Charter Amendment”)Charter/bylaw amendment or fiscal-year change · Form 8-K
- May 12, 2026Relmada Therapeutics Reports First Quarter 2026.Earnings release · press release
- Mar 20, 2026Relmada Therapeutics Reports Fourth Quarter.Earnings release · press release
- Mar 9, 2026On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”)Material agreement entered · Form 8-K
- Dec 15, 2025On December 12, 2025, the Board of Directors the Board of Directors of Relmada Therapeutics, Inc. (the “Company”) approved an amended and restated employment agreement with each of its executive officers, each to become effective as of January 1, 2026.Director or officer change · Form 8-K
- Nov 5, 2025On November 4, 2025, Relmada Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with an underwritten offering …Material agreement entered · Form 8-K
- Nov 4, 2025FDA Feedback on proposed NDV-01 Phase III Trials The FDA indicated that in the Bacillus Calmette-Guerin (BCG)-unresponsive setting, a single arm trial may be acceptable in a patient population refractory to other therapies, with the details of such a design to be discussed further with the FDA. The FDA also indicated …Regulation FD disclosure · Form 8-K
- Sep 17, 2025©2025 Relmada - All rights reserved Sepranolone A novel candidate, with potential to overcome the challenges of current therapies for compulsivity disorders.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…